DNDi is piloting a global SIM card service designed by The Foundation for Innovative New Diagnostics (FIND) to send clinical trial data securely from several clinical sites in the Democratic Republic of Congo (DRC). SIMs are small cards containing chips that are used in mobile phones and other connected devices to transmit data over the Internet in a secure manner.
BioCentury [17 April 2019]
“Atomwise unveils Chagas disease compounds from AIMS program”
Geneva, Switzerland and San Francisco, USA – 16 April 2019
Efforts to discover novel compounds against Chagas disease see early successes – part of Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards program to fast track drug development
Atomwise, Inc., a biotech company using artificial intelligence (AI) for drug discovery, and DNDi, a not-for-profit research and development organization working to deliver new treatments for neglected diseases, today announced that promising drug-like compounds have been discovered in a programme to develop first-in-class treatments for Chagas disease. The research collaboration is part of Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards programme.
Rio de Janeiro – 11 April 2019
The people affected by Chagas disease will claim this 14th of April as World Chagas Day in the hope of increasing global awareness, building on the progress already made against this disease, which has been neglected for more than a century
The International Federation of Associations of People Affected by Chagas disease (FINDECHAGAS) has launched an online petition through the platform change.org in support of the official declaration of April 14th as their World Day. This proposal will be tabled at the 72nd World Health Assembly, to be held in Geneva at the end of May 2019. The particular date has been chosen because on that same day, 110 years ago, the Brazilian doctor Carlos Chagas confirmed the first case of the disease in a child, called Berenice Soares.
Geneva, Switzerland – 2 April 2019
Continued close collaboration with founding partners will strengthen GARDP’s efforts to address AMR
GARDP is now an independent legal entity following a successful three-year incubation, hosted by DNDi. During this time, GARDP has already begun working with partners to develop antibiotics to tackle drug-resistant infections which pose a threat to global health and development, including the achievement of the Sustainable Development Goals.
Brazilian Society of Tropical Medicine [14 March 2019]
“Pandemic Response Box: Responding to a potential global medical emergency”
Horizon Magazine [6 March 2019]
“Preparing for the outbreak: helping research swing into action in central Africa”
Health Policy Watch [5 February 2019]
“New funding partnership to develop innovative drugs for leishmaniasis”
London/Geneva – 5 February 2019
Wellcome has committed over £10 million to DNDi to develop new treatments for leishmaniasis, one of the world’s most devastating parasitic diseases. The three-year partnership will enable DNDi and Wellcome to develop new combinations of entirely new, all-orally acting chemical entities, through a joint strategy that also harnesses the strengths of the pharmaceutical and biotechnology industries, academia, and product development partnerships.
The Telegraph [31 January 2019]
“Revolutionary sleeping sickness drug approved for use in DRC”
Paris/Genève, 30 Janvier 2019
La République Démocratique du Congo (RDC) a délivré une autorisation de mise sur le marché au fexinidazole pour le traitement de la trypanosomiase humaine africaine (THA) ou maladie du sommeil causée par le parasite Trypanosoma brucei gambiense. Cette approbation ouvre la voie à la distribution du fexinidazole, cette année, dans les pays où la maladie du sommeil est endémique, sachant qu’une autre soumission réglementaire est également prévue en Ouganda.
Paris/Geneva – 30 January 2019
Marketing authorization of fexinidazole for the treatment of Trypanosoma brucei gambiense human African trypanosomiasis, more commonly known as sleeping sickness, has been granted in the Democratic Republic of Congo (DRC). This approval paves the way for the distribution of fexinidazole in endemic countries this year, with another submission planned in Uganda.
Ghana News Agency [30 January 2019]
“UHAS broadens institutional collaborations”
ガンビア・トリパノソーマ (Trypanosoma brucei gambiense) によるヒト・アフリカ・トリパノソーマ症 (HAT、別名アフリカ睡眠病) の治療薬として、コンゴ民主共和国 (DRC) においてフェキシニダゾールの申請が承認されました。これにより、ウガンダで予定されている申請とともに、今年フェキシニダゾールを流行国において普及させる道が開かれました。
Science & Enterprise [30 January 2019]
“Compounds made available for pandemic drug discovery”
Chemical & Engineering News [29 January 2019]
“Open-source drug discovery takes aim at malaria and neglected diseases”
Pharmaceutical Technology [29 January 2019]
“MMV and DNDi create a response box to foster R&D for pandemic diseases”
IP Watch [29 January 2019]
“DNDi, MMV make 400 compounds available to boost pandemic disease research”
Geneva – 29 January 2019
Pandemic Response Box harnesses open and collaborative approaches to medical innovation
Medicines for Malaria Venture (MMV) and DNDi have launched the Pandemic Response Box to provide researchers with free access to 400 diverse compounds to accelerate the discovery of new treatments for life-threatening pandemic diseases.